Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Belcher

Pediatric Infectious Diseases Carmel, IN Medical Doctor

NPI 1407896392 CMS profile 245754

11455 N Meridian St, Suite 200, Carmel, IN 46032

Open in the dashboard

General payments

$579,066

762 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Belcher of Carmel, IN is reported in the CMS Open Payments database as having received $579,066 across 762 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94,481 86
2024 General $90,363 90
2023 General $112,135 115
2022 General $45,477 12
2021 General $13,610 6
2020 General $53,436 77
2019 General $169,563 376

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Belcher
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to Christopher Belcher were reported at $94,481. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year Christopher Belcher Pediatric Infectious Diseases median Middle half National median
2019 $169,563 $175 $34–$2,175 $163
2020 $53,436 $521 $34–$6,009 $114
2021 $13,610 $1,077 $39–$4,557 $132
2022 $45,477 $232 $53–$6,196 $149
2023 $112,135 $140 $52–$4,662 $160
2024 $90,363 $198 $52–$3,860 $164
2025 $94,481 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $189,173 242 payments
  2. Merck Sharp & Dohme Corporation $125,955 173 payments
  3. ParaPRO, LLC $103,615 6 payments
  4. Emergent BioSolutions Inc. $57,854 83 payments
  5. Sobi, Inc $57,373 146 payments
  6. Pfizer Inc. $43,561 47 payments
  7. La Jolla Pharmaceutical Company $348 3 payments
  8. Paratek Pharmaceuticals, Inc. $162 3 payments
  9. AbbVie, Inc. $128 6 payments
  10. Melinta Therapeutics, Inc. $109 7 payments
  11. Other $787 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $371,410 132 payments
  2. Honoraria $103,316 20 payments
  3. Travel and Lodging $75,163 351 payments
  4. Consulting Fee $15,514 12 payments
  5. Food and Beverage $13,574 243 payments
  6. Education $89 4 payments
Products named General payments · program years 2019–2025
  1. BEYFORTUS $104,618 92 payments
  2. VAXNEUVANCE $66,895 100 payments
  3. VAXCHORA $57,854 83 payments
  4. SYNAGIS $57,373 146 payments
  5. Natroba HeadLice $45,706 2 payments
  6. FLUZONE HIGH-DOSE $42,103 91 payments
  7. ABRYSVO $40,904 40 payments
  8. Natroba Head Lice $37,282 2 payments
  9. ENFLONSIA $34,142 27 payments
  10. FLUBLOK QUADRIVALENT $32,710 68 payments
  11. Other $129,422 274 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Infectious Disease: 268

Drug cost

$66

Median for Infectious Disease: $217,595

Branded share of claims

0%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azithromycin Generic 22 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABRYSVO
  • PFIZER INC. $30,343
$30,343 — —
MENQUADFI
  • SANOFI PASTEUR INC. $2,337
$2,337 — —
Natroba
  • ParaPRO, LLC $2,250
$2,250 — —
DALVANCE
  • AbbVie, Inc. $28
$28 — —
IXCHIQ
  • Valneva USA, Inc. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

762 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record